Isoprenoid geranylgeranylacetone inhibits human colon cancer cells through induction of apoptosis and cell cycle arrest

Anti-Cancer Drugs

Volumn 21, Issue 9, 2010, Pages 850-860

  Yoshikawa, Naoyuki ^a   Tsuno, Nelson H ^a,b   Okaji, Yurai ^a,c   Kawai, Kazushige ^b   Shuno, Yasutaka ^b   Nagawa, Hirokazu ^b   Oshima, Noriko ^d   Takahashi, Koki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Medical Research Division   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d TOHO UNIVERSITY   (Japan)

Author keywords

apoptosis; cell cycle arrest; colon cancer; geranylgeranylacetone; isoprenoid; p21; p27; phosphorylated retinoblastoma protein

Indexed keywords

BETA ACTIN; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; ISOPRENOID; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P27; RAS PROTEIN; RETINOBLASTOMA PROTEIN; RHO FACTOR; TEPRENONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; G1 PHASE; HUMANS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN;

EID: 77956418266     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833e53cf     Document Type: Article

References (46)

1. Hirakawa T, Rokutan K, Nikawa T, Kishi K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 1996; 111:345-357. (Pubitemid 26256722)
2. Hiruma Y, Nakahama K, Fujita H, Morita I. Vitamin K2 and geranylgeraniol, its side chain component, inhibited osteoclast formation in a different manner. Biochem Biophys Res Commun 2004; 314:24-30.
3. Hashimoto K, Morishige K, Sawada K, Tahara M, Shimizu S, Sakata M, et al. Geranylgeranylacetone inhibits lysophosphatidic acid-induced invasion of human ovarian carcinoma cells in vitro. Cancer 2005; 103:1529-1536.
4. Yasunari K, Maeda K, Minami M, Yoshikawa J. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001; 21:937-942.
5. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137 (Suppl):S101-S109. (Pubitemid 28294215)
6. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 2001; 61:4885-4891.
7. Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 2002; 62:6015-6020.
8. Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62:2708-2714.
9. Okada S, Yabuki M, Kanno T, Hamazaki K, Yoshioka T, Yasuda T, et al. Geranylgeranylacetone induces apoptosis in HL-60 cells. Cell Struct Funct 1999; 24:161-168.
10. Kanno T, Kobuchi H, Kajitani N, Utsumi T, Yano H, Horton AA, et al. Mevastatin, an inhibitor of HMG-CoA reductase, induces apoptosis, differentiation and Rap1 expression in HL-60 cells. Physiol Chem Phys Med NMR 2002; 34:1-15.
11. Hashimoto K, Morishige K, Sawada K, Ogata S, Tahara M, Shimizu S, et al. Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo. Biochem Biophys Res Commun 2007; 356:72-77.
12. Tanaka M, Obata T, Sasaki T. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer 1996; 32A:226-230.
13. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32:2747-2755.
14. Elson CE, Peffley DM, Hentosh P, Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc Soc Exp Biol Med 1999; 221:294-311.
15. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004; 229:567-585.
16. Ohizumi H, Masuda Y, Nakajo S, Sakai I, Ohsawa S, Nakaya K. Geranylgeraniol is a potent inducer of apoptosis in tumor cells. J Biochem 1995; 117:11-13.
17. Wang X, Wu J, Shidoji Y, Muto Y, Ohishi N, Yagi K, et al. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation. J Bone Miner Res 2002; 17:91-100.
18. Matsumoto Y, Hamashima H, Masuda K, Shiojima K, Sasatsu M, Arai T. The antibacterial activity of plaunotol against Staphylococcus aureus isolated from the skin of patients with atopic dermatitis. Microbios 1998; 96:149-155. (Pubitemid 128557795)
19. Burke YD, Stark MJ, Roach SL, Sen SE, Crowell PL. Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids 1997; 32:151-156.
20. Miquel K, Pradines A, Favre G. Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Biochem Biophys Res Commun 1996; 225:869-876.
21. Takeda Y, Nakao K, Nakata K, Kawakami A, Ida H, Ichikawa T, et al. Geranylgeraniol, an intermediate product in mevalonate pathway, induces apoptotic cell death in human hepatoma cells: death receptor-independent activation of caspase-8 with down-regulation of Bcl-xL expression. Jpn J Cancer Res 2001; 92:918-925.
22. Ohizumi H, Masuda Y, Yoda M, Hashimoto S, Aiuchi T, Nakajo S, et al. Induction of apoptosis in various tumor cell lines by geranylgeraniol. Anticancer Res 1997; 17:1051-1057.
23. Ushiyama S, Matsuda K, Asai F, Yamazaki M. Stimulation of prostaglandin production by (2E,6Z,10E)-7-hydroxymethyl-3,11,15-trimethyl-2,6,10,14-+ + + hexadecatetrae n-1-ol (plaunotol), a new anti-ulcer drug, in vitro and in vivo. Biochem Pharmacol 1987; 36:369-375.
24. Kohda I, Nagai H, Iwai M, Watanabe M, Yokoyama K, Tsujikawa K, et al. Effects of 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide on various ulcer models in rats. Chem Pharm Bull (Tokyo) 1991; 39: 1828-1831.
25. Okabe N, Okada M, Sakai T, Kuroiwa A. Effect of plaunotol on superoxide production activity in vivo. Dig Dis Sci 1995; 40:2321-2322.
26. Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, et al. Anti-angiogenic properties of plaunotol. Anticancer Drugs 2005; 16: 401-407.
27. Yamada J, Kawai K, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, et al. Plaunotol induces apoptosis of gastric cancer cells. Planta Med 2007; 73:1068-1073.
28. Yoshikawa N, Yamada J, Tsuno NH, Okaji Y, Kawai K, Tsuchiya T, et al. Plaunotol and geranylgeraniol induce caspase-mediated apoptosis in colon cancer. J Surg Res 2009; 153:246-253.
29. Yoshida M, Szente BE, Kiely JM, Rosenzweig A, Gimbrone MA Jr. Phosphorylation of the cytoplasmic domain of E-selectin is regulated during leukocyte-endothelial adhesion. J Immunol 1998; 161:933-941.
30. Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada T, Kitayama J, et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 1999; 81: 1274-1279.
31. Rokutan K, Teshima S, Kawai T, Kawahara T, Kusumoro K, Mizushima T, et al. Geranylgeranylacetone stimulates mucin synthesis in cultured guinea pig gastric pit cells by inducing a neuronal nitric oxide synthase. J Gastroenterol 2000; 35:673-681.
32. Ooie T, Takahashi N, Saikawa T, Nawata T, Arikawa M, Yamanaka K, et al. Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation 2001; 104:1837-1843.
33. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-776.
34. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
35. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdkinteracting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75:805-816.
36. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366:701-704.
37. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20 K regulatory subunit. Nature 1993; 366:707-710.
38. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211:90-98.
39. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66.
40. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78:67-74.
41. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994; 79:551-555.
42. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9:1149-1163.
43. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-1512.
44. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8:253-267.
45. Soussi T,Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12:303-312.
46. Nakazawa S, Tsuboi Y, Tsukamoto Y, Yoshino J, Okada M. Serum and stomach tissue levels of geranylgeranylacetone in patients. Int J Clin Pharmacol Ther Toxicol 1983; 21:267-270.